Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression
- Masaki Shiota1,*,
- Ario Takeuchi1,*,
- YooHyun Song1,2,*,
- Akira Yokomizo1,
- Eiji Kashiwagi1,
- Takeshi Uchiumi3,
- Kentaro Kuroiwa1,
- Katsunori Tatsugami1,
- Naohiro Fujimoto4,
- Yoshinao Oda2 and
- Seiji Naito1
- Departments of
1Urology
2Anatomic Pathology
3Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
4Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
- (Correspondence should be addressed to A Yokomizo; Email: yokoa{at}uro.med.kyushu-u.ac.jp)
Abstract
The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcription factor that is upregulated in CPRC. We aimed to elucidate the role of YB-1 in castration resistance of PCa and identify therapeutic potential of targeting YB-1. Using immunohistochemistry, we found that nuclear YB-1 expression significantly correlated with the Gleason score and AR expression in PCa tissues. In PCa cells, YB-1 regulated AR expression at the transcriptional level. Furthermore, YB-1 expression and nuclear localization were upregulated in CRPC cells. Overexpression of AR, as well as YB-1, conferred castration-resistant growth in LNCaP and 22Rv1 cells. Conversely, knocking down YB-1 resulted in suppressed cell growth and induced apoptosis, which was more efficient than knocking down AR in LNCaP cells. In other types of PCa cells, such as CRPC cells, knocking down YB-1 resulted in a significant reduction of cell growth. In conclusion, these findings suggested that YB-1 induces castration resistance in androgen-dependent PCa cells via AR expression. Thus, YB-1 may be a promising therapeutic target for PCa, as well as CRPC.
- Revision received 8 April 2011
- Accepted 6 June 2011
- © 2011 Society for Endocrinology